The authors examined 424 clinical HCC specimens and verified that HccFn-Co3O4 ferritin nanozymes could distinguish HCC tissues from normal liver tissues with a sensitivity of 63.5% and specificity of 79.1%, which was comparable with that of clinically used HCC specific marker alpha fetoprotein (AFP). Here, AFP is linked to hepatocellular carcinoma.